Table 5.
Response and Survival Correlates
| Characteristic | CVD
|
BCT
|
||||||
|---|---|---|---|---|---|---|---|---|
| No. | RR (%) | PFS (months) | OS (months) | No. | RR (%) | PFS (months) | OS (months) | |
| Performance status | ||||||||
| 0 | 131 | 12.2 | 3.0 | 10.5 | 132 | 21.2 | 5.3* | 11.1 |
| 1 | 64 | 17.2 | 2.4 | 5.8 | 68 | 16.2 | 3.6 | 6.9 |
| Sex | ||||||||
| Male | 147 | 15.0 | 3.0 | 9.7 | 133 | 21.8 | 5.0* | 10.2 |
| Female | 48 | 10.4 | 2.0 | 8.4 | 67 | 14.9 | 4.6 | 7.8 |
| No. of sites | ||||||||
| 1 | 44 | 15.9 | 3.0 | 11.5 | 48 | 18.8 | 5.9 | 14.0 |
| 2-3 | 115 | 14.8 | 2.9 | 8.6 | 111 | 18.9 | 4.7 | 8.9 |
| ≥ 4 | 36 | 8.3 | 1.7 | 5.1 | 41 | 22.0 | 3.6 | 6.0 |
| AJCC stage | ||||||||
| M1a | 23 | 26.1 | 3.2 | 13.1 | 15 | 20.0 | 5.5 | 13.0 |
| M1b | 26 | 26.9 | 5.6 | 16.2 | 34 | 23.5 | 5.8 | 13.3 |
| M1c | 141 | 9.9 | 1.7 | 7.9 | 144 | 17.4 | 4.0* | 7.6 |
| Prior IFN | ||||||||
| No | 120 | 14.2 | 3.0 | 8.9 | 120 | 21.7 | 4.7* | 8.0 |
| Yes | 75 | 13.3 | 1.7 | 8.6 | 80 | 16.3 | 4.8 | 10.8 |
Abbreviations: CVD, cisplatin, vinblastine, and dacarbazine; BCT, biochemotherapy; RR, response rate; PFS, progression-free survival; OS, overall survival; AJCC, American Joint Committee on Cancer; IFN, interferon alfa-2b.
*
P < .05.